818P Phase II confirmatory study of cemiplimab (350mg IV Q3W) in patients with locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Study 1540 Group 6

Authors :: B.G.M. Hughes
J.J. Grob
S.E. Bowyer
F.L. Day
R. Ladwa
B. Stein
E. Muñoz Couselo
N. Basset-Seguin
A. Guminski
L. Mortier
A. Hauschild
M.R. Migden
C. Schmults
S-Y. Yoo
J. Booth
F. Seebach
I. Lowy
M.G. Fury
D. Rischin
Source :: Annals of Oncology. 33:S921
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools